NASDAQ:OMER Omeros (OMER) Stock Price, News & Analysis → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free OMER Stock Alerts $3.16 +0.08 (+2.60%) (As of 12:40 PM ET) Add Compare Share Share Today's Range$3.11▼$3.2550-Day Range$3.05▼$4.8952-Week Range$0.92▼$7.80Volume95,427 shsAverage Volume556,332 shsMarket Capitalization$183.09 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Omeros alerts: Email Address Ad DTIHere’s how to start a “Weekend Side Hustle” from your sofaHere’s how you can start your very own “Weekend Side Hustle” right from the comfort of your sofa! It doesn't matter if you have a multi-million dollar retirement account… Or if you’re just starting out with a few thousand.Weekend after weekend! About Omeros Stock (NASDAQ:OMER)Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.Read More OMER Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OMER Stock News HeadlinesApril 17, 2024 | msn.comOmeros (OMER) Price Target Increased by 230.77% to 43.86April 16, 2024 | americanbankingnews.comOmeros (NASDAQ:OMER) Share Price Passes Above 200 Day Moving Average of $3.00April 23, 2024 | Insider Financial (Ad)Thousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.April 2, 2024 | marketwatch.comOmeros Shares Down 6% on Swing to 4Q LossApril 2, 2024 | finance.yahoo.comOmeros Corporation (NASDAQ:OMER) Q4 2023 Earnings Call TranscriptApril 2, 2024 | finance.yahoo.comQ4 2023 Omeros Corp Earnings CallApril 1, 2024 | investorplace.comOMER Stock Earnings: Omeros Misses EPS for Q4 2023April 1, 2024 | finance.yahoo.comOmeros Corporation Reports Fourth Quarter and Year-End 2023 Financial ResultsApril 23, 2024 | WealthPress (Ad)The system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.April 1, 2024 | finance.yahoo.comOmeros Corp (OMER) Reports Fourth Quarter and Year-End 2023 Financial ResultsMarch 27, 2024 | businesswire.comOmeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024March 19, 2024 | finance.yahoo.comOMER Aug 2024 3.000 putMarch 3, 2024 | finance.yahoo.comOMER Aug 2024 5.000 putMarch 1, 2024 | gurufocus.comOmeros Corporation - Special Call TranscriptMarch 1, 2024 | gurufocus.comQ3 2020 Omeros Corp Earnings Call TranscriptMarch 1, 2024 | gurufocus.comOmeros Corp at JPMorgan Healthcare Conference (Virtual) TranscriptMarch 1, 2024 | gurufocus.comQ4 2020 Omeros Corp Earnings Call TranscriptMarch 1, 2024 | gurufocus.comQ1 2021 Omeros Corp Earnings Call TranscriptMarch 1, 2024 | gurufocus.comOmeros Corp at Bank of America NAPA Healthcare Conference (Virtual) TranscriptMarch 1, 2024 | gurufocus.comQ2 2021 Omeros Corp Earnings Call TranscriptMarch 1, 2024 | gurufocus.comOmeros Corp Regulatory Update Call TranscriptMarch 1, 2024 | gurufocus.comQ3 2021 Omeros Corp Earnings Call TranscriptMarch 1, 2024 | gurufocus.comOmeros Corp Omidria Call TranscriptMarch 1, 2024 | gurufocus.comQ4 2021 Omeros Corp Earnings Call TranscriptMarch 1, 2024 | gurufocus.comQ1 2022 Omeros Corp Earnings Call TranscriptMarch 1, 2024 | gurufocus.comQ2 2022 Omeros Corp Earnings Call TranscriptMarch 1, 2024 | gurufocus.comQ3 2022 Omeros Corp Earnings Call TranscriptSee More Headlines Receive OMER Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Omeros and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2021Today4/23/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:OMER CUSIP68214310 CIK1285819 Webwww.omeros.com Phone(206) 676-5000Fax206-676-5005Employees196Year Founded1994Profitability EPS (Most Recent Fiscal Year)($1.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-117,810,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-1,916.35% Return on Assets-35.72% Debt Debt-to-Equity RatioN/A Current Ratio4.09 Quick Ratio4.09 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.40) per share Price / Book-7.70Miscellaneous Outstanding Shares57,940,000Free Float51,627,000Market Cap$178.46 million OptionableOptionable Beta1.34 Social Links The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Gregory A. Demopulos M.D. (Age 65)Co-Founder, Chairman, CEO & President Comp: $1.79MMr. Michael A. Jacobsen (Age 66)Chief Accounting Officer, VP of Finance & Treasurer Comp: $518.6kMr. Peter B. Cancelmo J.D. (Age 45)VP, General Counsel & Corporate Secretary Comp: $503.24kDr. Pamela Pierce Palmer M.D. (Age 61)Ph.D., Co-Founder Dr. George A. Gaitanaris M.D. (Age 67)Ph.D., Chief Scientific Officer & VP of Science Mr. Peter W. Williams (Age 56)Vice President of Human Resources Dr. Catherine A. Melfi Ph.D. (Age 65)Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems Ms. Nadia Dac (Age 54)VP & Chief Commercial Officer Dr. Andreas Grauer M.D. (Age 63)Chief Medical Officer More ExecutivesKey CompetitorsNektar TherapeuticsNASDAQ:NKTRLifecore BiomedicalNASDAQ:LFCRRigel PharmaceuticalsNASDAQ:RIGLSkye BioscienceNASDAQ:SKYEOrganigramNASDAQ:OGIView All CompetitorsInsiders & InstitutionsNomura Holdings Inc.Sold 62,338 shares on 3/27/2024Ownership: 0.609%Tower Research Capital LLC TRC Bought 5,378 shares on 2/13/2024Ownership: 0.013%Stifel Financial CorpSold 137,243 shares on 2/12/2024Ownership: 3.007%Capstone Investment Advisors LLCSold 49,500 shares on 2/12/2024Ownership: 0.000%Coldstream Capital Management Inc.Bought 8,335 shares on 2/9/2024Ownership: 0.045%View All Insider TransactionsView All Institutional Transactions OMER Stock Analysis - Frequently Asked Questions Should I buy or sell Omeros stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omeros in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" OMER shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OMER, but not buy additional shares or sell existing shares. View OMER analyst ratings or view top-rated stocks. How have OMER shares performed in 2024? Omeros' stock was trading at $3.27 on January 1st, 2024. Since then, OMER stock has decreased by 3.4% and is now trading at $3.16. View the best growth stocks for 2024 here. When is Omeros' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our OMER earnings forecast. How were Omeros' earnings last quarter? Omeros Co. (NASDAQ:OMER) posted its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.09. The biopharmaceutical company earned $30 million during the quarter, compared to analysts' expectations of $29.31 million. During the same period last year, the company posted ($0.39) EPS. What guidance has Omeros issued on next quarter's earnings? Omeros updated its first quarter 2024 earnings guidance on Monday, April, 1st. The company provided EPS guidance of -0.630--0.580 for the period. The company issued revenue guidance of -. What is Gregory A. Demopulos' approval rating as Omeros' CEO? 17 employees have rated Omeros Chief Executive Officer Gregory A. Demopulos on Glassdoor.com. Gregory A. Demopulos has an approval rating of 74% among the company's employees. What other stocks do shareholders of Omeros own? Based on aggregate information from My MarketBeat watchlists, some companies that other Omeros investors own include ACADIA Pharmaceuticals (ACAD), Exelixis (EXEL), Array Technologies (ARRY), Inovio Pharmaceuticals (INO), Ocular Therapeutix (OCUL), Alibaba Group (BABA), Sangamo Therapeutics (SGMO), Verastem (VSTM), Bausch Health Companies (BHC) and Celldex Therapeutics (CLDX). How do I buy shares of Omeros? Shares of OMER stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Omeros have any subsidiaries? The following companies are subsidiares of Omeros: Nura.Read More This page (NASDAQ:OMER) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Omeros Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
